NCT06496048View on ClinicalTrials.gov

Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC

PHASE3RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

September 14, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Relapsed Small Cell Lung Cancer
Interventions
DRUG

Lurbinectedin

Lurbinectedin 3.2 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)

DRUG

Irinotecan

Irinotecan 75 mg/m² intravenously Days 1 \& 8 q3wk

DRUG

Lurbinectedin

Lurbinectedin 2.0 mg/m2 administered by infusion on Day 1 of each cycle (q3wk)

DRUG

Topotecan

Topotecan 1.2 mg/m² intravenously Days 1-5 q3wk

Trial Locations (1)

Unknown

RECRUITING

Jilin Provincial Tumor Hospital, Jilin

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY